German Authorities Stonewall Pharma’s Transparency Demands
This article was originally published in The Pink Sheet Daily
Germany’s pharma industry is trying to force the government to reveal the decision-making process that led it to uphold the drug rebate and price freeze there, in the hope of avoiding fresh burdens in the future.
You may also be interested in...
Germany’s powerful health care watchdog G-BA, in its first full opinion on early added benefit assessment of medicines, says the process is fair and promotes real drug innovation, in sharp contrast to the biopharma industry which maintains it is a cost-cutting tool wielded by health insurance funds.
The Executive Director of the European Medicines Agency Guido Rasi’s dual goals of increasing safety and overall accountability undoubtedly will benefit patients and industry alike, but a grueling task lies ahead.
The German Upper House has proposed reducing the obligatory rebate manufacturers of original drug products must give health insurers and closing a loophole in the law on generic drug discount contracts.